secwatch.observer — SEC 8-K summary
======================================

Issuer:     IOVANCE BIOTHERAPEUTICS, INC. (IOVA)
CIK:        0001425205
Form:       8-K
Filed at:   2023-07-10T23:59:59+00:00
Accession:  0001104659-23-079364
Event type: other_material
Sentiment:  positive
Materiality: 0.75
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Iovance gets FDA positive feedback for TIL therapy in NSCLC; 26.1% ORR in 23 patients
--------------------------------------------------------------------------------

- FDA Type B meeting supports IOV-LUN-202 trial design for accelerated approval of LN-145 in post-anti-PD-1 advanced NSCLC.
- Preliminary data cut shows 26.1% ORR (6/23 patients) with one complete response and five partial responses; disease control rate 82.6%.
- Plans to enroll ~120 patients in registrational trial; enrollment expected complete H2 2024.
- Lifileucel BLA for advanced melanoma remains on Priority Review; PDUFA date Nov 25, 2023.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1425205/000110465923079364/0001104659-23-079364-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1425205/000110465923079364/tm2320915d3_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-23-079364

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer